A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial
Kane, John M., Eshet, Roy, Harary, Eran, Tohami, Orna, Elgart, Anna, Knebel, Helena, Sharon, Nir, Suett, Mark, Franzenburg, Kelli R., Davis, Glen L., Correll, Christoph U.
Published in CNS drugs (01.08.2024)
Published in CNS drugs (01.08.2024)
Get full text
Journal Article
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria
Kane, John M, Harary, Eran, Eshet, Roy, Tohami, Orna, Weiser, Mark, Leucht, Stefan, Merenlender-Wagner, Avia, Sharon, Nir, Davis, 3rd, Glen L, Suett, Mark, Franzenburg, Kelli R, Correll, Christoph U
Published in The Lancet. Psychiatry (01.12.2023)
Published in The Lancet. Psychiatry (01.12.2023)
Get more information
Journal Article
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia
Citrome, Leslie, Suett, Mark, Franzenburg, Kelli R, Eshet, Roy, Elgart, Anna, Davis Rd, Glen L, Harary, Eran, Tohami, Orna, Mychaskiw, Marko A, Kane, John M
Published in Neuropsychiatric disease and treatment (01.01.2024)
Published in Neuropsychiatric disease and treatment (01.01.2024)
Get full text
Journal Article